Mackenzie Financial
MYGN icon

Mackenzie Financial’s Myriad Genetics MYGN Stock Holding History

Mackenzie Financial’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.77M Buy
+1,535,702
New +$6.97M 0.01% 677
2017
Q4 		– Sell
-210,697
Closed -$7.62M – 838
2017
Q3 		$7.62M Hold
210,697
– – 0.04% 295
2017
Q2 		$5.44M Buy
+210,697
New +$4.47M 0.03% 303

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mackenzie Financial's MYGN Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Myriad Genetics (MYGN) in Q2 2026: 1,535,702 shares worth $8.77M. The stake represents 0.01% of the portfolio and ranks #677 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in MYGN as recently as Q3 2017.

Mackenzie Financial first reported a position in MYGN in Q2 2017 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Mackenzie Financial held 1,535,702 shares of Myriad Genetics worth $8.77M as of Q2 2026.
  • Myriad Genetics was a new Mackenzie Financial position in Q2 2026.
  • Myriad Genetics made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #677 holding.
  • Mackenzie Financial first reported a position in Myriad Genetics in Q2 2017 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.